Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

NCT ID: NCT00597025

Last Updated: 2020-03-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

375 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the impact of providing high protein supplementation in the form of a medical food bar containing 20grams of protein eath to hypoalbuminemic dialysis patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease Hypoalbuminemia Malnutrition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Center Hemodialysis patients

Group Type ACTIVE_COMPARATOR

Protein Food Bar Intelligent Indulgence

Intervention Type DIETARY_SUPPLEMENT

Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months

Group B

Center hemodialysis patients

Group Type ACTIVE_COMPARATOR

Protein Food Bar Intelligent Indulgence

Intervention Type DIETARY_SUPPLEMENT

Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days

Group C

Center Hemodialysis Patients

Group Type NO_INTERVENTION

No interventions assigned to this group

Group D

Peritoneal dialysis patients

Group Type ACTIVE_COMPARATOR

Protein Food Bar Intelligent Indulgence

Intervention Type DIETARY_SUPPLEMENT

Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.

Group E

Peritoneal dialysis patients

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Protein Food Bar Intelligent Indulgence

Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months

Intervention Type DIETARY_SUPPLEMENT

Protein Food Bar Intelligent Indulgence

Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days

Intervention Type DIETARY_SUPPLEMENT

Protein Food Bar Intelligent Indulgence

Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with ESRD undergoing center hemodialysis or peritoneal dialysis for more than 90 days.
* 18 years of age or older.
* Must have a reasonable expectation of remaining on treatment for at least 3 months.
* Must have an average serum albumin of \<3.5 g/dL over the three months prior to entry into the study.
* Must be able to understand and sign the informed consent.
* Must be willing and able to participate in nutrition interviews for determination of nutrient intake from conventional foods.

Exclusion Criteria

* Allergy to protein, milk, nuts or wheat.
* Documented ongoing acute infection or inflammatory process including treatment with antibiotics within a two week time of study entry.
* Severe acidosis defined as pre-dialysis serum bicarbonate levels of \<15 mEq/L.
* Presence of conditions that would affect normal response to repletion of protein and calories, such as gastrointestinal disorders including inflammatory bowel disease.
* Hospitalization for an infectious condition within 4 weeks prior to study entry.
* Planned surgery within the three month study period including planned kidney transplantation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Satellite Healthcare

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brigitte Schiller-Moran, MD

Role: PRINCIPAL_INVESTIGATOR

Satellite Healthcare, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Satellite Healthcare, Inc.

Mountain View, California, United States

Site Status

WellBound, Inc.

Mountain View, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SR017PB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Soy Protein in Early Diabetic Nephropathy
NCT00067678 COMPLETED PHASE1/PHASE2